New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis

New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis

The aim of the study was to assess efficacy and safety of newly developed specialized food product “SPP1” in patients with NASH. New specialized food product for clinical use (SPP1) consisted of (% of the RDAs): protein 8%; fat 7% (including ω-3 PUFA 40%); soluble dietary fiber 160%; phospholipids 2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current developments in nutrition 2021-06, Vol.5 (Supplement_2), p.851-851
Hauptverfasser: Morozov, Sergey, Sasunova, Armida, Sarkisyan, Varuzhan, Vorobiova, Valentina, Kochetkova, Alla, Isakov, Vasily
Format: Artikel
Sprache:eng
Schlagworte:
Medical Nutrition/Case Study Vignettes
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 851
container_issue Supplement_2
container_start_page 851
container_title Current developments in nutrition
container_volume 5
creator Morozov, Sergey
Sasunova, Armida
Sarkisyan, Varuzhan
Vorobiova, Valentina
Kochetkova, Alla
Isakov, Vasily
description The aim of the study was to assess efficacy and safety of newly developed specialized food product “SPP1” in patients with NASH. New specialized food product for clinical use (SPP1) consisted of (% of the RDAs): protein 8%; fat 7% (including ω-3 PUFA 40%); soluble dietary fiber 160%; phospholipids 25%; alpha-lipoic acid 33%; betaine 10%; minerals 13%–44%; vitamins (A, E, D3, K1, C, B1, B2, B6, B12, PP, Folic acid, Pantothenic acid, Biotin) 24%–140%. The study (NCT04308980) was approved by LEC and enrolled patients with diagnosis of NASH. Subjects were randomized to the following groups: those received iso-calorie diet (according to REE, by indirect calorimetry (Quarck RMR, Italy) alone (ICD) and iso-calorie diet + SPP1 (2 portions of SPP1 a day, 14 days)(ICD + SPP1 group). Safety was assessed based on clinical and laboratory data. Repeated measurements (baseline vs those on the 15th day of the study) of body composition (InBody, South Korea), and blood chemistry were compared. Non-parametric statistics (StatSoft, USA) was used for the analysis. The results of complex examination of 20 subjects (12 in ICD + SPP1 and 8 in ICD group) served as a source for the study. Initially, groups did not differ by age, sex, and BMI. The product was well tolerated. In contrast to ICD group, those in ICD + SPP1 group demonstrated greater decrease of weight: BMI initially (BMI0), Mean ± SD: 38.7 ± 5.4 kg/m2 vs BMI at the end-point (BMIEOT) 37.7 ± 5.1 kg/m2, P = 0.003 in ICD + SPP1 group, whereas in the ICD group BMI0 38.9 ± 7.2 kg/m2 vs BMIEOT 37.9 ± 7.3 kg/m2, P = 0.08. These results were reached predominantly by a decrease of the weight of fat: body fat weight (BFW)0 50.2 ± 10.7 kg vs BFWEOT 48.5 ± 10.8 kg, P = 0.002 in ICD + SPP1 group, whereas BFW0 48.9 ± 11.4 kg vs BFWEOT 46.8 ± 11.6 kg, P = 0.07 in ICD group. ALT and AST levels decreased in both groups, but in neither of them was statistically significant. The new specialized food product “SPP1” is safe, and well tolerated by patients with NASH. In combination with iso-calorie diet, it may increase efficacy of weight loss, predominantly by fat. Ministry of Science and Higher Education, #0529–2019-0055.
doi_str_mv 10.1093/cdn/nzab047_014
format Article
fullrecord <record><control><sourceid>oup_TOX</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8181283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cdn/nzab047_014</oup_id><els_id>S2475299123113692</els_id><sourcerecordid>10.1093/cdn/nzab047_014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2214-be99fe6702c01ed218a0954b8d66b78fccfd227c495e8ec232c91d22260885453</originalsourceid><addsrcrecordid>eNqNUc1KHEEQHkIERT177XNgst2989eXgNloIohZ2A05Nj3VNZkOs11Dd6-iJx8kuflkPklGVsQcAjlVUd9PFfVl2Yng7wVX8xlYP_N3puVFrbko3mQHsqjLXCol3r7q97PjGH9yzoVSquLqIHu4whu2GhGcGdwdWnZOZNkykN1CYo_3v1bLpXi8_82cZwvatM6b5Miz7y717CJSvjADBYfsk8PEVj3dRPYRU8LAzrrOgYFbtu6NZ6l_5pwO5PHJbh3QpA36xKhjV-RzMwD1NDhgqzRB1OM4LUsuHmV7nRkiHj_Xw-zb-dl68SW__Pr5YnF6mYOUoshbVKrDquYSuEArRWO4Kou2sVXV1k0H0FkpayhUiQ2CnEtQYprIijdNWZTzw-zDznfcthu0MN0WzKDH4DYm3GoyTv-NeNfrH3StG9EI2cwng9nOAALFGLB70Qqun4LSU1D6VVCT4t1OQdvxP8hqR8bpCdcOg47g0ANaFxCStuT-qf0DSKGuzQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis</title><source>Oxford Journals Open Access Collection</source><creator>Morozov, Sergey ; Sasunova, Armida ; Sarkisyan, Varuzhan ; Vorobiova, Valentina ; Kochetkova, Alla ; Isakov, Vasily</creator><creatorcontrib>Morozov, Sergey ; Sasunova, Armida ; Sarkisyan, Varuzhan ; Vorobiova, Valentina ; Kochetkova, Alla ; Isakov, Vasily</creatorcontrib><description>The aim of the study was to assess efficacy and safety of newly developed specialized food product “SPP1” in patients with NASH. New specialized food product for clinical use (SPP1) consisted of (% of the RDAs): protein 8%; fat 7% (including ω-3 PUFA 40%); soluble dietary fiber 160%; phospholipids 25%; alpha-lipoic acid 33%; betaine 10%; minerals 13%–44%; vitamins (A, E, D3, K1, C, B1, B2, B6, B12, PP, Folic acid, Pantothenic acid, Biotin) 24%–140%. The study (NCT04308980) was approved by LEC and enrolled patients with diagnosis of NASH. Subjects were randomized to the following groups: those received iso-calorie diet (according to REE, by indirect calorimetry (Quarck RMR, Italy) alone (ICD) and iso-calorie diet + SPP1 (2 portions of SPP1 a day, 14 days)(ICD + SPP1 group). Safety was assessed based on clinical and laboratory data. Repeated measurements (baseline vs those on the 15th day of the study) of body composition (InBody, South Korea), and blood chemistry were compared. Non-parametric statistics (StatSoft, USA) was used for the analysis. The results of complex examination of 20 subjects (12 in ICD + SPP1 and 8 in ICD group) served as a source for the study. Initially, groups did not differ by age, sex, and BMI. The product was well tolerated. In contrast to ICD group, those in ICD + SPP1 group demonstrated greater decrease of weight: BMI initially (BMI0), Mean ± SD: 38.7 ± 5.4 kg/m2 vs BMI at the end-point (BMIEOT) 37.7 ± 5.1 kg/m2, P = 0.003 in ICD + SPP1 group, whereas in the ICD group BMI0 38.9 ± 7.2 kg/m2 vs BMIEOT 37.9 ± 7.3 kg/m2, P = 0.08. These results were reached predominantly by a decrease of the weight of fat: body fat weight (BFW)0 50.2 ± 10.7 kg vs BFWEOT 48.5 ± 10.8 kg, P = 0.002 in ICD + SPP1 group, whereas BFW0 48.9 ± 11.4 kg vs BFWEOT 46.8 ± 11.6 kg, P = 0.07 in ICD group. ALT and AST levels decreased in both groups, but in neither of them was statistically significant. The new specialized food product “SPP1” is safe, and well tolerated by patients with NASH. In combination with iso-calorie diet, it may increase efficacy of weight loss, predominantly by fat. Ministry of Science and Higher Education, #0529–2019-0055.</description><identifier>ISSN: 2475-2991</identifier><identifier>EISSN: 2475-2991</identifier><identifier>DOI: 10.1093/cdn/nzab047_014</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Medical Nutrition/Case Study Vignettes</subject><ispartof>Current developments in nutrition, 2021-06, Vol.5 (Supplement_2), p.851-851</ispartof><rights>2021 American Society for Nutrition.</rights><rights>Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181283/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181283/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27901,27902,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/cdn/nzab047_014$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc></links><search><creatorcontrib>Morozov, Sergey</creatorcontrib><creatorcontrib>Sasunova, Armida</creatorcontrib><creatorcontrib>Sarkisyan, Varuzhan</creatorcontrib><creatorcontrib>Vorobiova, Valentina</creatorcontrib><creatorcontrib>Kochetkova, Alla</creatorcontrib><creatorcontrib>Isakov, Vasily</creatorcontrib><title>New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis</title><title>Current developments in nutrition</title><description>The aim of the study was to assess efficacy and safety of newly developed specialized food product “SPP1” in patients with NASH. New specialized food product for clinical use (SPP1) consisted of (% of the RDAs): protein 8%; fat 7% (including ω-3 PUFA 40%); soluble dietary fiber 160%; phospholipids 25%; alpha-lipoic acid 33%; betaine 10%; minerals 13%–44%; vitamins (A, E, D3, K1, C, B1, B2, B6, B12, PP, Folic acid, Pantothenic acid, Biotin) 24%–140%. The study (NCT04308980) was approved by LEC and enrolled patients with diagnosis of NASH. Subjects were randomized to the following groups: those received iso-calorie diet (according to REE, by indirect calorimetry (Quarck RMR, Italy) alone (ICD) and iso-calorie diet + SPP1 (2 portions of SPP1 a day, 14 days)(ICD + SPP1 group). Safety was assessed based on clinical and laboratory data. Repeated measurements (baseline vs those on the 15th day of the study) of body composition (InBody, South Korea), and blood chemistry were compared. Non-parametric statistics (StatSoft, USA) was used for the analysis. The results of complex examination of 20 subjects (12 in ICD + SPP1 and 8 in ICD group) served as a source for the study. Initially, groups did not differ by age, sex, and BMI. The product was well tolerated. In contrast to ICD group, those in ICD + SPP1 group demonstrated greater decrease of weight: BMI initially (BMI0), Mean ± SD: 38.7 ± 5.4 kg/m2 vs BMI at the end-point (BMIEOT) 37.7 ± 5.1 kg/m2, P = 0.003 in ICD + SPP1 group, whereas in the ICD group BMI0 38.9 ± 7.2 kg/m2 vs BMIEOT 37.9 ± 7.3 kg/m2, P = 0.08. These results were reached predominantly by a decrease of the weight of fat: body fat weight (BFW)0 50.2 ± 10.7 kg vs BFWEOT 48.5 ± 10.8 kg, P = 0.002 in ICD + SPP1 group, whereas BFW0 48.9 ± 11.4 kg vs BFWEOT 46.8 ± 11.6 kg, P = 0.07 in ICD group. ALT and AST levels decreased in both groups, but in neither of them was statistically significant. The new specialized food product “SPP1” is safe, and well tolerated by patients with NASH. In combination with iso-calorie diet, it may increase efficacy of weight loss, predominantly by fat. Ministry of Science and Higher Education, #0529–2019-0055.</description><subject>Medical Nutrition/Case Study Vignettes</subject><issn>2475-2991</issn><issn>2475-2991</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNUc1KHEEQHkIERT177XNgst2989eXgNloIohZ2A05Nj3VNZkOs11Dd6-iJx8kuflkPklGVsQcAjlVUd9PFfVl2Yng7wVX8xlYP_N3puVFrbko3mQHsqjLXCol3r7q97PjGH9yzoVSquLqIHu4whu2GhGcGdwdWnZOZNkykN1CYo_3v1bLpXi8_82cZwvatM6b5Miz7y717CJSvjADBYfsk8PEVj3dRPYRU8LAzrrOgYFbtu6NZ6l_5pwO5PHJbh3QpA36xKhjV-RzMwD1NDhgqzRB1OM4LUsuHmV7nRkiHj_Xw-zb-dl68SW__Pr5YnF6mYOUoshbVKrDquYSuEArRWO4Kou2sVXV1k0H0FkpayhUiQ2CnEtQYprIijdNWZTzw-zDznfcthu0MN0WzKDH4DYm3GoyTv-NeNfrH3StG9EI2cwng9nOAALFGLB70Qqun4LSU1D6VVCT4t1OQdvxP8hqR8bpCdcOg47g0ANaFxCStuT-qf0DSKGuzQ</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Morozov, Sergey</creator><creator>Sasunova, Armida</creator><creator>Sarkisyan, Varuzhan</creator><creator>Vorobiova, Valentina</creator><creator>Kochetkova, Alla</creator><creator>Isakov, Vasily</creator><general>Elsevier Inc</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202106</creationdate><title>New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis</title><author>Morozov, Sergey ; Sasunova, Armida ; Sarkisyan, Varuzhan ; Vorobiova, Valentina ; Kochetkova, Alla ; Isakov, Vasily</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2214-be99fe6702c01ed218a0954b8d66b78fccfd227c495e8ec232c91d22260885453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Medical Nutrition/Case Study Vignettes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morozov, Sergey</creatorcontrib><creatorcontrib>Sasunova, Armida</creatorcontrib><creatorcontrib>Sarkisyan, Varuzhan</creatorcontrib><creatorcontrib>Vorobiova, Valentina</creatorcontrib><creatorcontrib>Kochetkova, Alla</creatorcontrib><creatorcontrib>Isakov, Vasily</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current developments in nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Morozov, Sergey</au><au>Sasunova, Armida</au><au>Sarkisyan, Varuzhan</au><au>Vorobiova, Valentina</au><au>Kochetkova, Alla</au><au>Isakov, Vasily</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis</atitle><jtitle>Current developments in nutrition</jtitle><date>2021-06</date><risdate>2021</risdate><volume>5</volume><issue>Supplement_2</issue><spage>851</spage><epage>851</epage><pages>851-851</pages><issn>2475-2991</issn><eissn>2475-2991</eissn><abstract>The aim of the study was to assess efficacy and safety of newly developed specialized food product “SPP1” in patients with NASH. New specialized food product for clinical use (SPP1) consisted of (% of the RDAs): protein 8%; fat 7% (including ω-3 PUFA 40%); soluble dietary fiber 160%; phospholipids 25%; alpha-lipoic acid 33%; betaine 10%; minerals 13%–44%; vitamins (A, E, D3, K1, C, B1, B2, B6, B12, PP, Folic acid, Pantothenic acid, Biotin) 24%–140%. The study (NCT04308980) was approved by LEC and enrolled patients with diagnosis of NASH. Subjects were randomized to the following groups: those received iso-calorie diet (according to REE, by indirect calorimetry (Quarck RMR, Italy) alone (ICD) and iso-calorie diet + SPP1 (2 portions of SPP1 a day, 14 days)(ICD + SPP1 group). Safety was assessed based on clinical and laboratory data. Repeated measurements (baseline vs those on the 15th day of the study) of body composition (InBody, South Korea), and blood chemistry were compared. Non-parametric statistics (StatSoft, USA) was used for the analysis. The results of complex examination of 20 subjects (12 in ICD + SPP1 and 8 in ICD group) served as a source for the study. Initially, groups did not differ by age, sex, and BMI. The product was well tolerated. In contrast to ICD group, those in ICD + SPP1 group demonstrated greater decrease of weight: BMI initially (BMI0), Mean ± SD: 38.7 ± 5.4 kg/m2 vs BMI at the end-point (BMIEOT) 37.7 ± 5.1 kg/m2, P = 0.003 in ICD + SPP1 group, whereas in the ICD group BMI0 38.9 ± 7.2 kg/m2 vs BMIEOT 37.9 ± 7.3 kg/m2, P = 0.08. These results were reached predominantly by a decrease of the weight of fat: body fat weight (BFW)0 50.2 ± 10.7 kg vs BFWEOT 48.5 ± 10.8 kg, P = 0.002 in ICD + SPP1 group, whereas BFW0 48.9 ± 11.4 kg vs BFWEOT 46.8 ± 11.6 kg, P = 0.07 in ICD group. ALT and AST levels decreased in both groups, but in neither of them was statistically significant. The new specialized food product “SPP1” is safe, and well tolerated by patients with NASH. In combination with iso-calorie diet, it may increase efficacy of weight loss, predominantly by fat. Ministry of Science and Higher Education, #0529–2019-0055.</abstract><pub>Elsevier Inc</pub><doi>10.1093/cdn/nzab047_014</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 2475-2991
ispartof Current developments in nutrition, 2021-06, Vol.5 (Supplement_2), p.851-851
issn 2475-2991
2475-2991
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8181283
source Oxford Journals Open Access Collection
subjects Medical Nutrition/Case Study Vignettes
title New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T14%3A29%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Specialized%20Food%20Product%20%E2%80%9CSPP1%E2%80%9D%20in%20Combination%20With%20Iso-Calorie%20Diet%20Shows%20Better%20Efficacy%20Than%20the%20Diet%20Alone%20in%20Treatment%20of%20Non-alcoholic%20Steatohepatitis&rft.jtitle=Current%20developments%20in%20nutrition&rft.au=Morozov,%20Sergey&rft.date=2021-06&rft.volume=5&rft.issue=Supplement_2&rft.spage=851&rft.epage=851&rft.pages=851-851&rft.issn=2475-2991&rft.eissn=2475-2991&rft_id=info:doi/10.1093/cdn/nzab047_014&rft_dat=%3Coup_TOX%3E10.1093/cdn/nzab047_014%3C/oup_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/cdn/nzab047_014&rft_els_id=S2475299123113692&rfr_iscdi=true